Cross-source identity
National Provider Identifier 1508996141 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS NPPES |
| NPI 1508996141 |
| Registry identity — dermatologist, taxonomy 207N00000X |
| Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Medicare Part D | NPI 1508996141 | 34 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Tremfya(Guselkumab) | 23 | $248,353 |
| Cosentyx Sensoready (2 Pens)(Secukinumab) | 27 | $101,172 |
| Otezla(Apremilast) | 14 | $62,302 |
| Amjevita(Cf)(Adalimumab-Atto) | 20 | $22,352 |
| Cordran(Flurandrenolide) | 27 | $21,393 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.